1 Market Overview

• 1.1 Product Overview and Scope
• 1.2 Market Estimation Caveats and Base Year
• 1.3 Market Analysis by Type
  • 1.3.1 Overview: Global Pemafibrate Consumption Value by Type: 2021 Versus 2025 Versus 2032
  • 1.3.2 100 mg per vial
  • 1.3.3 200 mg per vial
• 1.4 Market Analysis by Combination Therapy
  • 1.4.1 Overview: Global Pemafibrate Consumption Value by Combination Therapy: 2021 Versus 2025 Versus 2032
  • 1.4.2 Combined use of Pemafibrate and Atorvastatin
  • 1.4.3 Combined use of Pemafibrate and Irbesartan
• 1.5 Market Analysis by Route of Administration
  • 1.5.1 Overview: Global Pemafibrate Consumption Value by Route of Administration: 2021 Versus 2025 Versus 2032
  • 1.5.2 Oral
  • 1.5.3 Enteral Administration
• 1.6 Market Analysis by Application
  • 1.6.1 Overview: Global Pemafibrate Consumption Value by Application: 2021 Versus 2025 Versus 2032
  • 1.6.2 Non-Small Cell Lung Cancer
  • 1.6.3 Melanoma
  • 1.6.4 Head and Neck Cancer
  • 1.6.5 Liver Cancer
  • 1.6.6 Others
• 1.7 Global Pemafibrate Market Size & Forecast
  • 1.7.1 Global Pemafibrate Consumption Value (2021 & 2025 & 2032)
  • 1.7.2 Global Pemafibrate Sales Quantity (2021-2032)
  • 1.7.3 Global Pemafibrate Average Price (2021-2032)

2 Manufacturers Profiles

• 2.1 BGI Genomics
  • 2.1.1 BGI Genomics Details
  • 2.1.2 BGI Genomics Major Business
  • 2.1.3 BGI Genomics Pemafibrate Product and Services
  • 2.1.4 BGI Genomics Pemafibrate Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.1.5 BGI Genomics Recent Developments/Updates
• 2.2 Betta Pharmaceuticals
  • 2.2.1 Betta Pharmaceuticals Details
  • 2.2.2 Betta Pharmaceuticals Major Business
  • 2.2.3 Betta Pharmaceuticals Pemafibrate Product and Services
  • 2.2.4 Betta Pharmaceuticals Pemafibrate Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.2.5 Betta Pharmaceuticals Recent Developments/Updates

3 Competitive Environment: Pemafibrate by Manufacturer

• 3.1 Global Pemafibrate Sales Quantity by Manufacturer (2021-2026)
• 3.2 Global Pemafibrate Revenue by Manufacturer (2021-2026)
• 3.3 Global Pemafibrate Average Price by Manufacturer (2021-2026)
• 3.4 Market Share Analysis (2025)
  • 3.4.1 Producer Shipments of Pemafibrate by Manufacturer Revenue ($MM) and Market Share (%): 2025
  • 3.4.2 Top 3 Pemafibrate Manufacturer Market Share in 2025
  • 3.4.3 Top 6 Pemafibrate Manufacturer Market Share in 2025
• 3.5 Pemafibrate Market: Overall Company Footprint Analysis
  • 3.5.1 Pemafibrate Market: Region Footprint
  • 3.5.2 Pemafibrate Market: Company Product Type Footprint
  • 3.5.3 Pemafibrate Market: Company Product Application Footprint
• 3.6 New Market Entrants and Barriers to Market Entry
• 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

• 4.1 Global Pemafibrate Market Size by Region
  • 4.1.1 Global Pemafibrate Sales Quantity by Region (2021-2032)
  • 4.1.2 Global Pemafibrate Consumption Value by Region (2021-2032)
  • 4.1.3 Global Pemafibrate Average Price by Region (2021-2032)
• 4.2 North America Pemafibrate Consumption Value (2021-2032)
• 4.3 Europe Pemafibrate Consumption Value (2021-2032)
• 4.4 Asia-Pacific Pemafibrate Consumption Value (2021-2032)
• 4.5 South America Pemafibrate Consumption Value (2021-2032)
• 4.6 Middle East & Africa Pemafibrate Consumption Value (2021-2032)

5 Market Segment by Type

• 5.1 Global Pemafibrate Sales Quantity by Type (2021-2032)
• 5.2 Global Pemafibrate Consumption Value by Type (2021-2032)
• 5.3 Global Pemafibrate Average Price by Type (2021-2032)

6 Market Segment by Application

• 6.1 Global Pemafibrate Sales Quantity by Application (2021-2032)
• 6.2 Global Pemafibrate Consumption Value by Application (2021-2032)
• 6.3 Global Pemafibrate Average Price by Application (2021-2032)

7 North America

• 7.1 North America Pemafibrate Sales Quantity by Type (2021-2032)
• 7.2 North America Pemafibrate Sales Quantity by Application (2021-2032)
• 7.3 North America Pemafibrate Market Size by Country
  • 7.3.1 North America Pemafibrate Sales Quantity by Country (2021-2032)
  • 7.3.2 North America Pemafibrate Consumption Value by Country (2021-2032)
  • 7.3.3 United States Market Size and Forecast (2021-2032)
  • 7.3.4 Canada Market Size and Forecast (2021-2032)
  • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

• 8.1 Europe Pemafibrate Sales Quantity by Type (2021-2032)
• 8.2 Europe Pemafibrate Sales Quantity by Application (2021-2032)
• 8.3 Europe Pemafibrate Market Size by Country
  • 8.3.1 Europe Pemafibrate Sales Quantity by Country (2021-2032)
  • 8.3.2 Europe Pemafibrate Consumption Value by Country (2021-2032)
  • 8.3.3 Germany Market Size and Forecast (2021-2032)
  • 8.3.4 France Market Size and Forecast (2021-2032)
  • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
  • 8.3.6 Russia Market Size and Forecast (2021-2032)
  • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

• 9.1 Asia-Pacific Pemafibrate Sales Quantity by Type (2021-2032)
• 9.2 Asia-Pacific Pemafibrate Sales Quantity by Application (2021-2032)
• 9.3 Asia-Pacific Pemafibrate Market Size by Region
  • 9.3.1 Asia-Pacific Pemafibrate Sales Quantity by Region (2021-2032)
  • 9.3.2 Asia-Pacific Pemafibrate Consumption Value by Region (2021-2032)
  • 9.3.3 China Market Size and Forecast (2021-2032)
  • 9.3.4 Japan Market Size and Forecast (2021-2032)
  • 9.3.5 South Korea Market Size and Forecast (2021-2032)
  • 9.3.6 India Market Size and Forecast (2021-2032)
  • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
  • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

• 10.1 South America Pemafibrate Sales Quantity by Type (2021-2032)
• 10.2 South America Pemafibrate Sales Quantity by Application (2021-2032)
• 10.3 South America Pemafibrate Market Size by Country
  • 10.3.1 South America Pemafibrate Sales Quantity by Country (2021-2032)
  • 10.3.2 South America Pemafibrate Consumption Value by Country (2021-2032)
  • 10.3.3 Brazil Market Size and Forecast (2021-2032)
  • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

• 11.1 Middle East & Africa Pemafibrate Sales Quantity by Type (2021-2032)
• 11.2 Middle East & Africa Pemafibrate Sales Quantity by Application (2021-2032)
• 11.3 Middle East & Africa Pemafibrate Market Size by Country
  • 11.3.1 Middle East & Africa Pemafibrate Sales Quantity by Country (2021-2032)
  • 11.3.2 Middle East & Africa Pemafibrate Consumption Value by Country (2021-2032)
  • 11.3.3 Turkey Market Size and Forecast (2021-2032)
  • 11.3.4 Egypt Market Size and Forecast (2021-2032)
  • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
  • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

• 12.1 Pemafibrate Market Drivers
• 12.2 Pemafibrate Market Restraints
• 12.3 Pemafibrate Trends Analysis
• 12.4 Porters Five Forces Analysis
  • 12.4.1 Threat of New Entrants
  • 12.4.2 Bargaining Power of Suppliers
  • 12.4.3 Bargaining Power of Buyers
  • 12.4.4 Threat of Substitutes
  • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

• 13.1 Raw Material of Pemafibrate and Key Manufacturers
• 13.2 Manufacturing Costs Percentage of Pemafibrate
• 13.3 Pemafibrate Production Process
• 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

• 14.1 Sales Channel
  • 14.1.1 Direct to End-User
  • 14.1.2 Distributors
• 14.2 Pemafibrate Typical Distributors
• 14.3 Pemafibrate Typical Customers

15 Research Findings and Conclusion

16 Appendix

• 16.1 Methodology
• 16.2 Research Process and Data Source

According to our (Global Info Research) latest study, the global Pemafibrate market size was valued at US$ 216 million in 2025 and is forecast to a readjusted size of US$ 337 million by 2032 with a CAGR of 8.6% during review period.
Pemabebt is an immune checkpoint inhibitor used to treat certain types of cancer, particularly non-small cell lung cancer and melanoma. It works by inhibiting the PD-1/PD-L1 pathway, enhancing the patient's immune system's ability to recognize and attack tumor cells. Pemabebt targets the immune evasion mechanisms on the surface of tumor cells, helping to restore normal immune function and improve the body's ability to fight tumors. This drug is typically used in combination with other cancer treatments to enhance effectiveness and prolong patient survival. The clinical application of Pemabebt is mainly focused on treating advanced cancer patients, particularly those who have not responded to traditional therapies.In 2025, global Pemafibrate production reached approximately 1.2 million units.
Pemabebt, as an immune checkpoint inhibitor, is becoming one of the important drugs in the field of cancer treatment, particularly showing broad market prospects in the treatment of non-small cell lung cancer, melanoma, and other cancers. As immunotherapy gradually becomes one of the mainstream treatments for cancer, the market demand for Pemabebt is also on the rise, especially for patients with advanced cancer where traditional treatments are limited or ineffective. Immune checkpoint inhibitors enhance the immune system's response to tumor cells, not only effectively prolonging the patient's survival but also potentially causing fewer side effects, offering a clear advantage over traditional chemotherapy. This positions Pemabebt with significant market potential in the treatment of advanced cancers, particularly in indications such as non-small cell lung cancer. As its therapeutic effects are further validated, the market demand for Pemabebt continues to grow.
This report is a detailed and comprehensive analysis for global Pemafibrate market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Pemafibrate market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Pemafibrate market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Pemafibrate market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Pemafibrate market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Pemafibrate
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Pemafibrate market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include BGI Genomics, Betta Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Pemafibrate market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
100 mg per vial
200 mg per vial
Market segment by Combination Therapy
Combined use of Pemafibrate and Atorvastatin
Combined use of Pemafibrate and Irbesartan
Market segment by Route of Administration
Oral
Enteral Administration
Market segment by Application
Non-Small Cell Lung Cancer
Melanoma
Head and Neck Cancer
Liver Cancer
Others
Major players covered
BGI Genomics
Betta Pharmaceuticals
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Pemafibrate product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Pemafibrate, with price, sales quantity, revenue, and global market share of Pemafibrate from 2021 to 2026.
Chapter 3, the Pemafibrate competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Pemafibrate breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Pemafibrate market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Pemafibrate.
Chapter 14 and 15, to describe Pemafibrate sales channel, distributors, customers, research findings and conclusion.